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FHIT Gene Expression in Lung Cancer Cell-lines and Evaluation 
of Its Effects with Chemotherapeutic Agents on Apoptosis.
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Genetic alterations are well known phenomena in lung cancer. Applica-
tion of gene therapy for better survival is a challenge for the future. The 
fragile histidine triad (FHIT) gene located at the 3p14.2 locus plays an 
important role in the pathogenesis of lung cancer. We have earlier re-
ported that loss of FHIT expression is common in biopsy tissue of lung 
cancer patients and methylation of its promoter is one cause of gene 
activation (Mol Cancer Res, 2006). In the present study, two human 
lung cancer derived cell-lines, NCI 520 and NCI H460, were screened 
for the presence of FHIT expression and the effect of transfection of 
FHIT gene along with chemotherapeutic agents on apoptosis. 
Loss of heterozygosity was observed at all the three loci using three mi-
crosatellite polymorphic markers (D3S1300, D3S1312 and D3S1313) 
as was used for the tissue sample analysis in our earlier study. In the 
NCI H460 cell-line, we evaluated and compared the effects of FHIT 
re-introduction on cell proliferation and apopotosis. Further, the paren-
tal and FHIT-reintroduced NCI H460 cell-lines were compared with 
respect to apoptosis induced by three chemotherapeutic drugs namely, 
gemcitabine, irinocam and paclitaxel.
RT-PCR analysis demonstrated that both the cell-lines showed com-
plete absence of FHIT transcript. Loss of heterozygosity analysis in 
both cell-lines revealed LOH with respect to D3S1300 and D3S1313 
markers in NCI 520 cell-line whereas the NCI H460 cell-line showed 
complete deletion of these three loci. The NCI H460 cell-line also 
showed total absence of FHIT transcript or protein expression. There-
fore, it was used as a model for the re-introduction of FHIT cDNA. 
The FHIT cDNA isolated from normal human cervical tissue was 
cloned into pCR 3.1 mammalian expression vector. This FHIT cDNA 
corresponded to the coding region of the FHIT gene. The NCI H460 
cells were transfected stably with the vector containing FHIT cDNA. 
The transfected cell-line expressed FHIT protein at the moderate levels 
which was conﬁrmed by western blotting. Soft agar colony formation 
assay showed that the FHIT transfected cell-line showed smaller and 
fewer number of tumor colonies as compared to the untransfected cell-
line reconﬁrming the tumor suppresser properties of FHIT. Next we 
looked at apoptosis induction by chemotherapeutic drugs in the FHIT 
transfected and untransfected cell-lines. Apoptosis was measured by the 
cell death detection ELISA and the WST-1 cytotoxicity assay. Overall, 
the effect of gemcitabine in inducing apoptosis was more than irinocam 
and paclitaxel. Further, the FHIT transfected cell-line showed greater 
induction of apoptosis as compared to untransfected cell-line with all 
three drugs tested. The degree of increase in apoptosis induction due to 
the re-introduction of FHIT was modest. 
This experimental study implicates a pro-apoptotic function for the 
FHIT protein which is also corroborated by the tissue analysis earlier 
(Mol Cancer Res, 2006). Molecular based gene therapy using FHIT 
may supplement conventional therapy which may result in better 
survival. However, the observations from the bench top to the bedside 
remains a challenge and a hope for a better future for patients with lung 
cancer.
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Background: MicroRNAs (miRNAs) are a family of small, non-
coding RNA species regulating expression of numerous target genes 
including tumour suppressor genes and oncogenes. Investigation of 
miRNAs and their regulation of target genes relevant to lung cancer 
will likely contribute to understanding of tumourigenesis as well as 
potentially providing a basis from which to design novel therapeutics.
Methods: To identify candidate miRNAs of functional signiﬁcance 
in lung cancer, 474 miRNA genes listed in miRBase (http://microrna.
sanger.ac.uk) v9.0 were mapped to positions in Agilent 44B high 
resolution arrayCGH data obtained in 132 subjects with primary lung 
cancer (60 squamous cell carcinomas, 72 adenocarcinomas) treated by 
resection. The group included 40 women and 10 never smokers, and 
had a mean age of 65.4 (±9.2) years. Fold change in gene copy number 
for probes immediately ﬂanking the positions of miRNA genes was 
computed from the signal log ratios of tumour DNA to normal female 
DNA in arrayCGH experiments. 
Results: 97 miRNAs were mapped to regions of abnormal copy num-
ber in this data. Applying this approach to other published lung cancer 
arrayCGH datasets revealed 22 miRNAs in common, and the mature 
miRNA of one of these (miR-218) had also been reported as signiﬁ-
cantly underexpressed in lung cancer. miR-218 therefore emerged as 
a candidate miRNA with possible tumour suppressor function in lung 
cancer. Reduced expression of mature miR-218 was conﬁrmed by qRT-
PCR (Ambion) in a set of 22 lung cancers - mean expression relative to 
normal lung = 0.31±0.34. 
Conclusions: Our approach yielded a list of candidate miRNAs that 
may contribute to lung tumourigenesis and identiﬁed a miRNA (miR-
218), underexpressed in lung cancer, which could have tumour suppres-
sor function. In a larger number of tumours we now intend to conﬁrm 
reduced expression of mature miR-218 and check that the mechanism 
is low gene copy number using an independent method (qRT-PCR), 
before proceeding to functional transfection studies in model systems. 
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